Koichiro Yoneyama

6PUBLICATIONS
11CO-AUTHORS
Forensic epidemiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 12, 2024
Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy.

Midori Shima, Nobuaki Suzuki, Hidekazu Nishikii

|Aug 02, 2023
Clinical pharmacology of emicizumab for the treatment of hemophilia A.

Koichiro Yoneyama, Christophe Schmitt, Agnès Portron

|Sep 21, 2021
A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A.

Koichiro Yoneyama, Christophe Schmitt, Tiffany Chang

|Sep 14, 2019
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.

Midori Shima, Keiji Nogami, Sayaka Nagami

|Jan 04, 2018
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.

Midori Shima, Hideji Hanabusa, Masashi Taki

|Dec 08, 2017
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

Koichiro Yoneyama, Christophe Schmitt, Naoki Kotani

Pageof 1

Frequent Collaborators

3 joint publications

Christophe Schmitt

2 joint publications

Ryu Kasai

1 joint publications

Hiroki Yoshida

1 joint publications

Sayaka Nagami